// App-Quantinova.ai

: Safety, Pharmacokinetics, and Pharmacodynamics of AZD3366 Alone and in Combination With Aspirin and Ticagrelor in Healthy Subjects

Researchers

Presenter

  • Dimitris Kardassis

Principal Investigators

  • Ann-Charlotte Egnell

  • Magnus Åstrand

  • Samuel J Daniels

  • Celeste Frickleton

  • Carl Whatling

  • Ola Fjellstrom

  • Anders Gabrielsen

Medical Centers

  • Early Clinical Development, AstraZeneca, Gothenburg, Sweden,

  • Early Clinical Development, AstraZeneca, Alderly Park, United Kingdom

  • Clinical Pharmacology and Safety Sciences,, AstraZeneca, Gothenburg, Sweden

  • Clinical Pharmacology and Safety Sciences,, AstraZeneca, Gothenburg, Sweden

  • Projects, AstraZeneca, Gothenburg, Sweden

  • Translational Science and Experimental Medicine, AstraZeneca, Gaithersburg, MD

  • Early Clinical Development, AstraZeneca, Gothenburg, Sweden,

Locations

  • Sweden

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ticagrelor

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Controlled

  • Cohort

Phase

  • I

Study Id's

  • NCT04588727

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved